1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Nektar Therapeutics

Nektar Therapeutics

NKTR
Nektar TherapeuticsUS flagNASDAQ Global Select
68.67
USD
+3.83
- -
1.34BMarket Cap

Total Valuation

Nektar Therapeutics carries a market capitalization of 1.34B, placing it among publicly traded companies globally. Its enterprise value stands at 918.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.34B
Enterprise Value918.78M

Share Statistics

Nektar Therapeutics currently has 29.47M shares outstanding.

Shares Outstanding29.47M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 25.24, and the price-to-book ratio stands at -0.37.

PE RatioN/A
PS Ratio25.24
PB Ratio-0.37
P/TBV Ratio2.44
P/FCF Ratio-6.90
P/OCF Ratio-6.89

Enterprise Valuation

EV / Sales16.52
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Nektar Therapeutics maintains a current ratio of 10.21, meaning it holds 10.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.43, indicating elevated leverage, while an interest coverage ratio of -4.25 demonstrates limited ability to service its debt obligations.

Current Ratio10.21
Quick Ratio9.92
Debt / Equity14.43
Debt / EBITDA-0.67
Interest Coverage-4.25

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-31.01
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.72

Taxes

Income Tax-126,000.00
Effective Tax RateN/A

Stock Price Statistics

Nektar Therapeutics's stock has gained approximately 180.51471% over the past 52 weeks. The 50-day moving average sits at 66.41, while the 200-day moving average is 62.52.

Beta (5Y)N/A
52-Week Price Change180.51471%
50-Day Moving Average66.41
200-Day Moving Average62.52
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Nektar Therapeutics generated 55.63M in revenue and converted that into -158.10M in net income, yielding earnings per share of -8.10. EBITDA reached -123.91M, while operating income came in at -124.66M.

Revenue55.63M
Gross Profit44.77M
Operating Income-124.66M
Pretax Income-152.21M
Net Income-158.10M
EBITDA-123.91M
EBIT-124.66M
Earnings Per Share (EPS)-8.10

Balance Sheet

Nektar Therapeutics holds 568.60M in cash and equivalents against 83.16M in total debt, resulting in a net debt position of -149.58M. Total book value stands at -3.81B, with working capital of 531.33M providing operational flexibility.

Cash & Cash Equivalents568.60M
Total Debt83.16M
Net Debt-149.58M
Equity (Book Value)-3.81B
Book Value Per Share-194.97
Working Capital531.33M

Cash Flow

Nektar Therapeutics produced -203.76M in operating cash flow over the past twelve months. After subtracting -187,000.00 in capital expenditures, free cash flow totaled -203.94M - equivalent to -10.45 per share.

Operating Cash Flow-203.76M
Capital Expenditures-187,000.00
Free Cash Flow-203.94M
FCF Per Share-10.45

Margins

Nektar Therapeutics operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -224.08 and net profit margin of -284.18 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-224.08
Pretax Margin-273.59
Profit Margin-284.18
EBITDA Margin-222.73

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-50.57
FCF Yield-14.50

Stock Splits

Nektar Therapeutics's most recent stock split took place on June 9, 2025 with a 15:1 split ratio.

Last Split Date6/9/2025
Split Ratio15:1

Scores

Nektar Therapeutics posts an Altman Z-Score of -2.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-2.11